You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK1

Showing 1 - 25 of 613
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

Active, not recruiting
  • Chronic Graft vs Host Disease
  • Chronic Graft-Versus-Host Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 29, 2022

Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Sarcoidosis
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Jan 24, 2023

Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Granuloma Annulare
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Dec 19, 2022

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022

Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
May 19, 2022

Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Itacitinib (INCB039110)
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jul 14, 2022

Lupus Nephritis Trial in Assiut (Anti JAK1,2)

Active, not recruiting
  • Lupus Nephritis
  • Anti JAK1,2
  • Assiut, Assuit, Egypt
    Manal Hassanien
Jun 21, 2022

Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

Recruiting
  • Rheumatoid Arthritis
  • +4 more
  • filgotinib 200mg/day
  • subcutaneous tocilizumab 162mg/biweekly
  • Nagasaki, Japan
    Nagasaki University Hospital
Oct 23, 2021

Bronchiolitis Obliterans Trial in Houston (Itacitinib, Itacitinib Adipate)

Recruiting
  • Bronchiolitis Obliterans
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle

Recruiting
  • Metastatic Leiomyosarcoma
  • +17 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 13, 2022

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM),

No longer available
  • Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
  • +3 more
  • Bethesda, Maryland
  • +2 more
Apr 6, 2022

Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

Recruiting
  • Myeloproliferative Neoplasm
  • +5 more
  • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
  • Aspirin 81 mg
  • Ottawa, Ontario, Canada
    The Ottawa Hospital
Apr 19, 2022

Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Bone
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Jan 4, 2023

Myelofibrosis Trial in Canton (Jaktinib Hydrochloride Tablet)

Recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • Canton, Ohio
    Site 01
Aug 18, 2022

Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

Not yet recruiting
  • Vitiligo
  • Effect of Drug
  • JAK-2 inhibitor
  • Topical corticosteroid
  • (no location specified)
Mar 19, 2022

Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm
  • Hangzhou, Zhejiang, China
    The Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Healthy Trial in New Haven (Ritlecitinib 50 mg, Ritlecitinib 200 mg)

Completed
  • Healthy
  • Ritlecitinib 50 mg
  • Ritlecitinib 200 mg
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Feb 4, 2022

Vitiligo, JAK Inhibitor Trial in Canada, United States (Ruxolitinib 1.5% cream, NB-UVB phototherapy)

Recruiting
  • Vitiligo
  • JAK Inhibitor
  • Ruxolitinib 1.5% cream
  • NB-UVB phototherapy
  • Fountain Valley, California
  • +13 more
Jul 6, 2022

Phase 1 Trial in Brussels (PF-04965842, Midazolam)

Completed
  • Phase 1
  • Brussels, Belgium
    Pfizer Clinical Research Unit
Mar 19, 2020

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 21, 2022